- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04737369
Multimodal Neuromonitoring (MMNM)
Multimodal Neuromonitoring: an Explorative Study in Neurocritical Care Patients
Theoretical Framework & Background
Cortical spreading depressions (CSD) and seizures, are crucial in the development of delayed cerebral ischemia and poor functional outcome in patients suffering from acute brain injuries such as subarachnoid hemorrhage. Multimodal neuromonitoring (MMNM) provides the unique possibility in the sedated and mechanically ventilated patients to record these electrophysiological phenomena and relate them to measures of cerebral ischemia and malperfusion. MMNM combines invasive (e.g. electrocorticography, cerebral microdialysis, brain tissue oxygenation) and noninvasive (e.g. neuroimaging, continuous EEG) techniques. Additionally, cerebral microdialysis can measure the unbound extracellular drug concentrations of sedatives, which potentially inhibit CSD and seizures in various degrees, beyond the blood-brain barrier without further interventions.
Hypotheses
- Online multimodal neuromonitoring can accurately detect changes in neuronal metabolic demand and pathological neuronal bioelectrical changes in highly vulnerable brain tissue.
- Online multimodal neuromonitoring can accurately detect the impact of pathological neuronal bioelectrical changes on metabolic demand in highly vulnerable brain tissue.
- The occurrence and duration of pathological neuronal bioelectrical changes are dependent on sedatives and antiepileptic drug concentrations
- The occurrence and duration of pathological neuronal bioelectrical changes have a negative impact on functional and neurological long-term patient outcome.
- Simultaneous invasive and non-invasive multimodal neuromonitoring can identify a clear relationship of both methods regarding pathological neuronal bioelectrical changes and metabolic brain status.
Methods
Systematic analysis of MMNM measurements following standardized criteria and correlation of electrophysiological phenomena with cerebral metabolic changes in all included patients. In a second step neuroimaging, cerebral extracellular sedative drug concentrations and neurological functional outcome, will be correlated with both electrophysiologic and metabolic changes. Due to numerous high-resolution parameters, machine learning algorithms will be used to correlate comprehensive data on group and individual levels following a holistic approach.
Level of originality
Extensive, cutting edge diagnostic methods are used to get a better insight into the pathophysiology of electrophysiological and metabolic changes during the development of secondary brain damage. Due to the immense amount of high-resolution data, a computer-assisted evaluation will be applied to identify relationships in the development of secondary brain injury. For the first time systematic testing of several drug concentrations beyond the blood-brain barrier will be performed. With these combined methods, we will be able to develop new cerebroprotective treatment concepts on an individual basis.
Study Overview
Status
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Johannes Herta, MD PhD
- Phone Number: +43 (0)1 40400-25770
- Email: johannes.herta@meduniwien.ac.at
Study Contact Backup
- Name: Johannes Koren, MD PhD
- Phone Number: +43 (0)1 80110-2524
- Email: johannes.koren@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Department of Neurosurgery, Medical University of Vienna
-
Contact:
- Johannes Herta, MD PhD
- Phone Number: +43 (0)1 40400-25770
- Email: johannes.herta@meduniwien.ac.at
-
Contact:
- Johannes Koren, MD PhD
- Phone Number: +43 (0)1 80110-2524
- Email: johannes.koren@meduniwien.ac.at
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Individuals between 18-80 years with poor grade aneurysmal SAH (World Federation Neurosurgical Societies >3), severe ICH (ICH Score >3) or severe TBI (Glasgow Coma Scale < 9). The diagnosis of SAH, ICH and TBI will be established by computed tomography (CT).
- Individuals that are unlikely to regain consciousness within the following 48 hours.
- Individuals that are expected to survive for the next 48 hours.
Exclusion Criteria:
- Individuals younger than 18 years old and older than 80 years.
- Pregnant women (documented via positive ß-HCG test).
- Patients, who do not want to participate in the study. As the patient is not able to consent prior to the study, information about the study details will be given to the patient in case of clinical improvement. The patient information sheet will be handed out.
Thereafter, the patient has the possibility to withdraw permission of study-participation.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Count of SD during electrocorticography
Time Frame: up to 21 days
|
Count of cortical spreading depolarization (SD) during continuous electrocorticography
|
up to 21 days
|
Daily pattern duration of CSD during electrocorticography
Time Frame: up to 21 days
|
Duration of cortical spreading depression (CSD) per hour during continuous electrocorticography
|
up to 21 days
|
Daily pattern duration of NCSE during electrocorticography
Time Frame: up to 21 days
|
Duration of nonconvulsive status epilepticus (NCSE) per hour during continuous electrocorticography
|
up to 21 days
|
Daily pattern duration of RPPIIC during electrocorticography
Time Frame: up to 21 days
|
Duration of rhythmic or periodic EEG patterns on the ictal-interictal continuum (RPPIIC) per hour during continuous electrocorticography
|
up to 21 days
|
Daily duration of metabolic crisis
Time Frame: up to 21 days
|
Duration of metabolic crisis (defined as Lactate Pyruvate ratio [LPR] > 40 and lactate higher than 4 mmol/l) during continuous electrocorticography
|
up to 21 days
|
Daily duration of mitochondrial dysfunction
Time Frame: up to 21 days
|
Duration of mitochondrial dysfunction (defined as LPR > 40, Pyruvate > 70 μmol/l and partial brain tissue oxygenation [PbtO2] > 20 mmHg) during continuous electrocorticography
|
up to 21 days
|
Daily duration of ischemia
Time Frame: up to 21 days
|
Duration of ischemia (defined as PbtO2 < 15 mmHg and cerebral perfusion pressure [CPP] < 60 mmHg) during continuous electrocorticography
|
up to 21 days
|
Daily duration of elevated intracranial pressure (ICP)
Time Frame: up to 21 days
|
Duration of elevated intracranial pressure (defined as ICP > 22 mmHg) during continuous electrocorticography
|
up to 21 days
|
Neuropharmacology Cmax)
Time Frame: up to 21 days
|
Cmax of routinely used sedative drug concentrations in blood and brain (Esketamine, Midazolam and Propofol)
|
up to 21 days
|
Neuropharmacology (AUC)
Time Frame: up to 21 days
|
AUC of routinely used sedative drug concentrations in blood and brain (Esketamine, Midazolam and Propofol)
|
up to 21 days
|
Neuropharmacology (t1/2)
Time Frame: up to 21 days
|
t1/2 of routinely used sedative drug concentrations in blood and brain (Esketamine, Midazolam and Propofol)
|
up to 21 days
|
Neuroimaging
Time Frame: up to 28 days
|
Absence or presence of hypoperfusion or ischemic infarctions in neuroimaging
|
up to 28 days
|
Functional patient outcome
Time Frame: up to 6 months
|
modified Rankin Scale
|
up to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Johannes Herta, MD PhD, Department of Neurosurgery, Medical University of Vienna
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Intracranial Hemorrhages
- Brain Injuries
- Hemorrhage
- Brain Injuries, Traumatic
- Seizures
- Subarachnoid Hemorrhage
- Cerebral Hemorrhage
Other Study ID Numbers
- MMNM01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seizures
-
Eisai Inc.CompletedPartial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized SeizuresUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedGeneralized Tonic Clonic SeizuresKorea, Republic of, United States, Austria, Serbia, India, Spain, Poland, Malaysia, China, Bulgaria, Denmark, Greece, Hungary, United Kingdom, Belarus, France, Montenegro, Philippines, Romania, Russian Federation, Slovakia, Ukraine, Lebano... and more
-
Lundbeck LLCCompletedAdult Refractory Complex Partial SeizuresUnited States
-
University Hospital, BordeauxCompletedPsychogenic Nonepileptic Seizures (PNESs)France
-
Xenon Pharmaceuticals Inc.Worldwide Clinical TrialsRecruitingPrimary Generalized Tonic-Clonic SeizuresUnited States, Australia, Bulgaria, Poland, Czechia, Canada, Portugal, Croatia, Italy, Spain
-
UCB Biopharma SRLRecruitingStereotypical Prolonged SeizuresUnited States, Bulgaria, China, Czechia, Germany, Hungary, Italy, Japan, Poland, Spain, United Kingdom, France, Australia
-
UCB Biopharma SRLEnrolling by invitationStereotypical Prolonged SeizuresUnited States, Bulgaria, China, Czechia, Germany, Hungary, Italy, Japan, Poland, Spain, United Kingdom, Australia
-
Central Hospital, Nancy, FranceCompletedPsychogenic Non-epileptic SeizuresFrance
-
ValexfarmCompletedEpilepsy | Complex Partial Seizures | Simple Partial Seizures | Partial Seizures With Secondary GeneralizationRussian Federation
-
University of Alabama at BirminghamBaylor College of Medicine; Yale UniversityRecruitingConvulsion, Non-Epileptic | Functional SeizuresUnited States